News
This page is intended for media, analysts, and investors.
Read the latest Mereo BioPharma news
Together with patient communities, healthcare professionals, commercial partners and with the support of investors, we are constantly making progress on our mission. We are committed to regularly updating our investors, analysts, and the media on this progress. Here you can read the latest Mereo news and learn about events at which we are speaking.
If you would like to get in touch, you will find ways to contact us on this page.
Mereo BioPharma to Present at the 44th Annual J.P. Morgan Healthcare Conference
London, January 8, 2026 - Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 1:30pm PT / 9:30pm GMT. The webcast is available through this link.
Mereo BioPharma Provides Corporate Update
London, January 12, 2026 - Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today provided an update on its programs, setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, which is being studied for the treatment of alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD), and revised its cash runway guidance.
Mereo BioPharma Announces Phase 3 ORBIT and COSMIC Results for Setrusumab (UX143) in Osteogenesis Imperfecta
London, December 29, 2025 – Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical stage biopharmaceutical company focused on rare diseases, today announced results from the Phase 3 ORBIT and COSMIC studies for setrusumab (UX143) in Osteogenesis Imperfecta (OI).
Mereo BioPharma and Oncologie Enter into Global Licensing Agreement for Navicixizumab
Mereo BioPharma Group plc and Oncologie, Inc. today announced a global license agreement for the development and commercialization of navicixizumab, an anti-DLL4/VEGF bispecific antibody currently being evaluated in an ongoing Phase 1b study in combination with paclitaxel in patients with advanced heavily pretreated ovarian cancer.
Mereo BioPharma Appoints Suba Krishnan, M.D. as Senior Vice President of Clinical Development
LONDON and REDWOOD CITY, Calif. , Nov. 23, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH) (“Mereo” or “the Company”), a clinical stage biopharmaceutical company focused on oncology and rare diseases, today announces the appointment of Suba Krishnan , M.D.
Mereo BioPharma Announces Interim Financial Results for the Six Months Ended June 30, 2020 and Provides Corporate Update
On track to initiate Phase 1b/2 etigilimab (Anti-TIGIT) combination study in Q4 2020 Enrolment resumed in Phase 2 study of alvelestat in Alpha-1 Antitrypsin Deficiency and initiated placebo-controlled Phase 1b/2 clinical trial in COVID-19 respiratory disease Partnering discussions continue for
Mereo BioPharma Receives FDA Rare Pediatric Disease Designation for Setrusumab for the Treatment of Osteogenesis Imperfecta
Mereo BioPharma Group a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announces that the U.S. Food and Drug Administration (“FDA”) has granted Rare Pediatric Disease designation to setrusumab for the treatment of osteogenesis imperfecta (“OI”).
Mereo BioPharma Announces Initiation of Placebo-Controlled Phase 1b/2 Clinical Trial with Alvelestat in COVID-19 Respiratory Disease
LONDON and REDWOOD CITY, Calif. , Aug. 25, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), “Mereo” or “the Company”, a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced the initiation of a Phase 1b/2 placebo-controlled
Mereo BioPharma Strengthens Management Team; Appoints John Lewicki, PhD, as Chief Scientific Officer and Ann Kapoun, PhD, as SVP of Translational Research and Development
LONDON and REDWOOD CITY, Calif. , June 30, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), “Mereo” or “the Company”, a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced the appointments of John Lewicki , PhD, as Chief
Mereo BioPharma Announces Financial Results for the Year Ended December 31, 2019
Operational progress, positioned for clinical milestones in oncology and rare diseases LONDON and REDWOOD CITY, Calif. , June 16, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), “Mereo” or “the Company”, a clinical-stage biopharmaceutical company focused on oncology and
Mereo BioPharma Announces Completion of $70 Million Private Placement
Plans to Develop Etigilimab (Anti-TIGIT) Alongside Rare Disease Product Portfolio LONDON and REDWOOD CITY, Calif. , June 04, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH) today announces the completion of a $70 million (£56 million) private placement (the
Business Update and Directorate Change
LONDON and REDWOOD CITY, Calif. , March 27, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH) “Mereo” or “the Company”, a clinical-stage biopharmaceutical company focused on rare diseases, today provided a general business update, including a current assessment of the
Mereo BioPharma Announces Positive Feedback from Type B End-of-Phase 2 Meeting with the FDA and Outlines Pivotal Phase 3 Pediatric Study Design for Setrusumab in Osteogenesis Imperfecta
LONDON and REDWOOD CITY, Calif. , Feb. 28, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), "Mereo" or the "Company," a clinical stage biopharmaceutical company focused on rare diseases, today announced the successful completion of a Type B End-of-Phase 2 meeting with
Mereo BioPharma Announces Equity Investment of $3 Million from New U.S. Institutional Investor
LONDON and REDWOOD CITY, Calif. , Feb. 19, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), "Mereo" or the "Company," today announced that it has entered into a Securities Purchase Agreement (the “Agreement”) with a new U.S.-based institutional healthcare investor.
Mereo BioPharma Announces Update on Distribution Related to Contingent Value Rights Following Recent Oncologie Licensing Agreement for Navicixizumab
LONDON and REDWOOD CITY, Calif. , Feb. 12, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), "Mereo" or the "Company," today announced that it is distributing approximately 1.2 cents cash per Contingent Value Right (“CVR”), a total of approximately $463,748 , related to
